Infographic: What’s in Europe’s Immuno-oncology Pipeline? – Labiotech.eu (blog)

Posted: February 13, 2017 at 3:46 am

While some might accuse the field of being over-hyped, immuno-oncology continues to attract attentionandinvestment for its potential to cure cancer. What new therapies are European biotech cooking up?

Since the dawn of immuno-oncology broke with checkpoint inhibitors, innovative therapies like Keytruda and Rituxanfrom big pharma have taken the world by storm. European biotechs pipeline is full of potential successors born from T-Cell Receptors (TCR), monoclonal antibodies (mAbs), T-Cell Fragments, Chimeric Antigen Receptor-modified T cells (CAR-T) and tumor-infiltrating lymphocytes (TIL).

Medigene is leading the TCR race, with Immunocore not far behind with its fragments. Celyad and Cellectis are fierce rivalsin CAR-T therapy and in a dead heat. The antibody pipeline is jam-packed with biotechs at every stage of development. TILs are a lesser-known area of immuno-oncology, but Cellular Therapeutics has developed one of the most advanced programs in the field.

Check out how far companies and theirtherapies have come in immuno-oncology!

Major thanks to Celyad, Medigene and Accellerate Partners for their guidance!

Infographic by Justine Braguy ; Image from Agor2012/shutterstock.com

More here:
Infographic: What’s in Europe’s Immuno-oncology Pipeline? – Labiotech.eu (blog)

Related Post